Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

Mumbai: Global pharma major Lupin Limited has announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the ...

Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution (0.03%) under abbreviated new drug application (ANDA). The approved drug is a generic of Atrovent Nasal Spray (0.03%) (Boehringer Ingelheim ...

Mumbai: Global pharma major Lupin Limited has announced its inclusion in prestigious S&P Global Sustainability Yearbook 2025, ...

Additionally, the US Food and Drug Administration (USFDA) granted approval for Lupin’s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% ...

Lupin share price fell nearly 2 percent in the early trade on February 11 despite the company received United States Food and Drug Administration (USFDA) approval for nasal spray. At 09:23am ...

Lupin: Lupin Ltd received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for ipratropium bromide nasal solution (0.03%).